Tolvaptan Extension Study in Participants With ADPKD
Status:
Completed
Trial end date:
2016-02-29
Target enrollment:
Participant gender:
Summary
To demonstrate whether tolvaptan modifies ADPKD progression as measured by changes from
Baseline (from Study 156-04-251) in total kidney volume (TKV) and renal function.
Phase:
Phase 3
Details
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.